Xintela AB (publ) Stock Nasdaq Stockholm
Equities
SE0007756903
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | 78K 7.13K 9.75K | Capitalization | 148M 13.52M 18.49M |
---|---|---|---|---|---|
Net income 2022 | -66M -6.03M -8.25M | Net income 2023 | -54M -4.94M -6.75M | EV / Sales 2022 | - |
Net cash position 2022 | 8.34M 763K 1.04M | Net cash position 2023 | 7.81M 714K 976K | EV / Sales 2023 | 1,797 x |
P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-2.1
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 31.28% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 67 | 08-12-31 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 12-12-31 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 17-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 20-12-31 |
Chairman | 67 | 10-12-31 | |
Director/Board Member | 64 | 21-12-31 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |